Ambiq Micro Adds Singapore Listing to Existing NYSE Stock, One Year After IPO

Ambiq Micro just added a second stock ticker. The chipmaker, listed on the New York Stock Exchange under AMBQ, began a dual listing on the Main Board of the Singapore Exchange Securities Trading Limited under the ticker AMQ, according to a July 29, 2026 announcement from law firm Cooley LLP, which advised on the deal.

This is not a company fleeing New York. Ambiq wants more shareholders, specifically ones in Asia. The company makes ultra-low power semiconductors for edge AI, chips that let devices run AI workloads without draining batteries or needing constant cloud connections. Demand for that technology is growing fast as more gadgets try to run AI locally instead of shipping data back and forth to server farms.

The Singapore listing complements rather than replaces the NYSE listing. Cooley's announcement describes it as "expanding investor access across Asia and supporting the company's long-term growth strategy."

The IPO Backstory

Cooley also advised Ambiq on its original NYSE initial public offering, which raised $96 million in July 2025. Ambiq has been a public US company for about a year before adding the Singapore listing, executing a second phase of a capital-markets plan rather than making its public debut.

Dual listings like this are a standard strategy for tech and semiconductor companies that want exposure to Asian institutional investors, family offices, and retail traders without abandoning their US listing or the liquidity that comes with it. Singapore in particular has been positioning itself as a hub for tech listings as competition with Hong Kong and other regional exchanges heats up.

Who Did the Work

The Cooley team advising Ambiq was cross-border. Singapore-based partner Timothy Pitrelli and counsel Steven Holm handled the local listing mechanics. On the US side, partner Michael Platt, Chicago partner-in-charge Christina Roupas, partner Courtney Tygesson, associate Mateus Aboud, special counsel Alaina DeBona and associate David Brinton rounded out the team, per the firm's announcement.

Cooley is not a small shop. The firm says it has nearly 1,400 lawyers across 19 offices in the US, Asia and Europe, with a total workforce topping 3,000. Landing both the original NYSE IPO and the follow-on Singapore listing for the same client is solid business for the firm and signals Cooley's cross-border semiconductor and tech practice is active in the Asia-Pacific listings market.

What's Actually Notable Here

Cooley's announcement contains no hint of regulatory problems, shareholder disputes, or financial distress driving this move. It reads like what it is: a company trying to widen its investor base while capital is flowing hard toward anything tagged "edge AI."

A fair skeptic might ask whether dual listings actually deliver the liquidity and valuation benefits companies claim, or whether they mostly generate legal and compliance fees without moving the stock price much. Dual listings do raise that question in corporate finance circles. Cooley's release, being a law firm's own promotional material, naturally doesn't address it. It's an advertisement for legal work, not an independent assessment of whether the Singapore listing will actually boost Ambiq's valuation or trading volume.

Cooley's announcement is a legal-services press release, not a market report. It doesn't include the numbers an investor would want: opening price on SGX, shares offered, or lock-up terms for existing holders.

Investors watching AMBQ on the NYSE will want to see whether the Singapore listing attracts new capital or just adds a second reporting burden. The real test comes in trading volume and shareholder composition over the coming quarters.